Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 7/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434853 | 0.85 | MAPT (0.60) | MAPTALDH1A1LMNAMAPK1HTT | |
| SCHEMBL5693187 | 0.84 | MAPT (0.69) | MAPTALDH1A1ALDH1A3LMNAMAPK1 | |
| SCHEMBL4433632 | 0.84 | LMNA (0.74) | MAPTALDH1A1LMNAMAPK1HTT | |
| SCHEMBL6629924 | 0.84 | MAPT (0.58) | MAPTALDH1A1LMNAMAPK1HTT | |
| SCHEMBL31443837 | 0.84 | MAPT (0.58) | MAPTALDH1A1LMNAMAPK1HTT | |
| SCHEMBL13156273 | 0.84 | MAPT (0.75) | MAPTALDH1A1LMNAMAPK1HTT | |
| SCHEMBL20167799 | 0.84 | MAPT (0.58) | MAPTALDH1A1ALDH1A3LMNAMAPK1 | |
| SCHEMBL30522472 | 0.84 | MAPT (0.58) | MAPTALDH1A1ALDH1A3LMNAMAPK1 | |
| SCHEMBL30998112 | 0.83 | MAPT (0.63) | MAPTALDH1A1LMNAMAPK1HTT | |
| SCHEMBL4435451 | 0.83 | MAPT (0.63) | MAPTALDH1A1LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488519-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PF MEDICAMENT (FR) | 2015-06-10 | — | — | EP | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20060281789-A1 | Protein kinase inhibitors | KYOWA HAKKO KOGYO CO., LTD (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1650194-A1 | PROTEIN KINASE INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | DPYD, TYMP, ABCB1 | MAPT 3678/4885ALDH1A1 170/4885ALDH1A3 2263/4885 |
| US-20060281789-A1 | Protein kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | MAPT 1336/4885ALDH1A1 2999/4885ALDH1A3 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.